Last week, shares of King Pharmaceuticals popped after the FDA approved Embeda, King's drug to treat moderate to severe chronic pain.
Although its primary ingredient is morphine, the pills also contain a second drug called naltrexone.
If the pill is taken normally, it will release the morphine. However if it is crushed or chewed, the naltrexone is released, canceling out the morphine; in other words it's much harder for this pain killer to be abused. King expects to launch the drug in September.
Could Embeda signal the beginnings of a safer way to treat pain?
“We think it heralds a new age for stronger pain medication, says King Pharma CEO Brian Markison on Fast Money.
He goes on to say that although other companies are working on similar treatments, “we’re way ahead of the competition.”
Find out what else Marksion has to say. Watch the video now.